This observational study will assess the efficacy and safety of RoActemra/Actemra (Tocilizumab) in smoking versus non-smoking patients with rheumatoid arthritis. Data from patients treated in routine clinical practice with intravenous RoActemra/Actemra will be collected for 12 months each.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01337388?cond=%22Arthritis%22&lup_s=07/14/2011&lup_d=30
